

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	6235-75996-01
	Application Number	10/582,654
	Filing Date	February 20, 2008
	First Named Inventor	Ono
	Art Unit	1643
	Examiner Name	Lynn Anne Bristol

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. (optional)	Document Number Number-Kind Code (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant
/L.B./		US-2003/0103979	06/05/2003	Leung <i>et al.</i>
↑		US-2003/0147894	08/07/2003	Fukushima <i>et al.</i>
		US-2003/0157100	08/21/2003	Fukushima <i>et al.</i>
		US-2003/0157577	08/21/2003	Fukushima <i>et al.</i>
		US-2003/0202975	10/30/2003	Tedder
		US-2003/0211108	11/13/2003	Fukushima <i>et al.</i>
		US-2004/0001828	01/01/2004	Tuscano <i>et al.</i>
		US-2004/0073013	04/15/2004	Fukushima <i>et al.</i>
		US-2008/0107654	05/08/2008	Kikuchi <i>et al.</i>
		US-2008/0286280	11/20/2008	Kallmeyer <i>et al.</i>
		US-2009/0311718	12/17/2009	Fukushima <i>et al.</i>
		US-4,946,778	08/07/1990	Ladner <i>et al.</i>
		US-5,618,920	04/08/1997	Robinson <i>et al.</i>
		US-5,789,554	08/04/1998	Leung <i>et al.</i>
		US-5,837,242	11/17/1998	Holliger <i>et al.</i>
		US-5,840,344	11/24/1998	Fukushima
		US-5,885,574	03/23/1999	Elliott
		US-5,892,020	04/06/1999	Mezes <i>et al.</i>

EXAMINER SIGNATURE:	/Lynn Bristol/	DATE CONSIDERED:	08/16/2011
------------------------	----------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Please place an "X" in this column if English translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	6235-75996-01
	Application Number	10/582,654
	Filing Date	February 20, 2008
	First Named Inventor	Ono
	Art Unit	1643
	Examiner Name	Lynn Anne Bristol

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. (optional)	Document Number Number-Kind Code (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant
/L.B./		US-5,977,322	11/02/1999	Marks <i>et al.</i>
↑		US-6,579,692	06/17/2003	Fukushima
↑		US-6,719,972	04/13/2004	Gribben <i>et al.</i>
↑		US-6,759,043	07/06/2004	Fukushima
↑		US-7,115,373	10/03/2006	Hashida <i>et al.</i>
↑		US-7,456,260	11/25/2008	Rybak <i>et al.</i>

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. (optional)	Foreign Patent Document Country Code-Number-Kind Code (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant	T**
/L.B./		AU 2004297111 A1	06/23/2005	Chugai Seiyaku Kabushiki Kaisha	
↑		EP 0 721 015 B1	07/10/1996	Chugai Seiyaku Kabushiki Kaisha	
↑		EP 1 035 132 B1	09/13/2000	Chugai Seiyaku Kabushiki Kaisha	
↑		EP 1 262 548 A1	12/4/2002	Chugai Seiyaku Kabushiki Kaisha	
↑		EP 1 327 680 B1	07/16/2003	Chugai Seiyaku Kabushiki Kaisha	
↑		EP 1 369 431 A1	12/10/2003	Kirin Beer Kabushiki Kaisha	
↑		EP 1 712 565 A1	10/18/2006	Chugai Seiyaku Kabushiki Kaisha	
↑		EP 1 757 686 A1	02/28/2007	Chugai Seiyaku Kabushiki Kaisha	
↑		JP 7236475 (w/English abstract)	09/12/1995	Chugai Seiyaku Kabushiki Kaisha	

EXAMINER SIGNATURE:	/Lynn Bristol/	DATE CONSIDERED:	08/16/2011
------------------------	----------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Please place an "X" in this column if English translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	6235-75996-01
	Application Number	10/582,654
	Filing Date	February 20, 2008
	First Named Inventor	Ono
	Art Unit	1643
	Examiner Name	Lynn Anne Bristol

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. (optional)	Foreign Patent Document Country Code-Number-Kind Code (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant	T**
/L.B./		JP 10-510842 (w/English abstract)	10/20/1998	ZymoGenetics, Inc.	
↑		JP 11-092500 (w/English abstract)	04/06/1999	Chugai Seiyaku Kabushiki Kaisha	
		JP 2000-95800 (w/English abstract)	04/04/2000	Amgen	
		WO 91/16928 A1	11/14/1991	Cell-Tech Limited	
		WO 92/19759 A1 (w/English abstract)	11/12/1992	Chugai Seiyaku Kabushiki Kaisha	
		WO 94/13806 A1	06/23/1994	The Dow Chemical Company	
		WO 96/26648 A1	09/06/1996	The Procter & Gamble Company	
		WO 96/36360 A1	11/21/1996	Regents of the University of Minnesota	
		WO 97/32601 A1 (w/English Abstract)	09/12/1997	Chugai Seiyaku Kabushiki Kaisha	
		WO 97/34632 A1	09/25/1997	Immunomedics, Inc.	
		WO 96/40218 A1	12/19/1996	ZymoGenetics, Inc.	
		WO 98/44001 A1	10/08/1998	Commonwealth Scientific and Industrial Research Organisation	
		WO 99/03495 A1	01/28/1999	Beth Israel Deaconess Medical Center, Inc.	
		WO 99/12973 A1 (w/English Abstract)	03/18/1999	Chugai Seiyaku Kabushiki Kaisha	
		WO 99/17364 A1	04/08/1999	Raytheon Company	
		WO 00/53634 A1 (w/English Abstract)	09/14/2000	Chugai Seiyaku Kabushiki Kaisha	
		WO 03/002607 A1	01/09/2003	Leung	

EXAMINER SIGNATURE:	/Lynn Bristol/	DATE CONSIDERED:	08/16/2011
------------------------	----------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Please place an "X" in this column if English translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	6235-75996-01
	Application Number	10/582,654
	Filing Date	February 20, 2008
	First Named Inventor	Ono
	Art Unit	1643
	Examiner Name	Lynn Anne Bristol

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. (optional)	Foreign Patent Document Country Code-Number-Kind Code (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant	T**
/L.B./		WO 03/107218 A1 (w/English Abstract)	12/24/2003	Celestar Lexico-Sciences, Inc.	
↑		WO 2005/056602 A1 (w/English Abstract)	06/23/2005	Chugai Seiyaku Kabushiki Kaisha	
↑		WO 2005/056603 A1 (w/English Abstract)	06/23/2005	Chugai Seiyaku Kabushiki Kaisha	
		WO 2005/056605 A1 (w/English Abstract)	06/23/2005	Chugai Seiyaku Kabushiki Kaisha	
		WO 2005/056798 A1 (w/English Abstract)	06/23/2005	Chugai Seiyaku Kabushiki Kaisha	
		WO 2005/100560 A1 (w/English Abstract)	10/27/2005	Chugai Seiyaku Kabushiki Kaisha	
		WO 2008/071394 A1	06/19/2008	F. Hoffmann-LaRoche AG	

OTHER DOCUMENTS

Examiner Initials*	Cite No. (optional)	OTHER DOCUMENTS	T**
/L.B./		AVENT <i>et al.</i> , "Monoclonal antibodies that recognize different membrane proteins that are deficient in Rh _{null} human erythrocytes. One group of antibodies reacts with a variety of cells and tissues whereas the other group is erythroid-specific," <i>Biochem. J.</i> , 251:499-505 (1988)	
↑		BARTLEY <i>et al.</i> , "Identification and Cloning of a Megakaryocyte Growth and Development Factor That is a Ligand for the Cytokine Receptor Mpl," <i>Cell</i> , 77:1117-1124 (1994)	
↑		BAZIL <i>et al.</i> , "Apoptosis of human hematopoietic progenitor cells induced by crosslinking of surface CD43, the major sialoglycoprotein of leukocytes," <i>Blood</i> , 86:502-511 (1995)	
↑		BAZZONI <i>et al.</i> , "Chimeric tumor necrosis factor receptors with constitutive signaling activity," <i>Proc. Natl. Acad. Sci. USA</i> , 92(12):5376-5580 (1995)	
↑		BERGER <i>et al.</i> , "Inhibition of intractable nucleases with ribonucleoside-vanadyl complexes: isolation of messenger ribonucleic acid from resting lymphocytes," <i>Biochemistry</i> , 18(23):5143-5149 (1979)	
↑		BOGER and GOLDBERG, "Cytokine receptor dimerization and activation: prospects for small molecule agonists," <i>Bioorganic and Medicinal Chemistry</i> , 9(3):557-562 (2001)	
↑		BROOKE <i>et al.</i> , "Human lymphocytes interact directly with CD47 through a novel member of the signal regulatory protein (SIRP) family," <i>J. Immunol.</i> , 173:2562-2570 (2004)	
↑		BROWN <i>et al.</i> , "Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins," <i>J. Cell Biology</i> , 111(6 Pt 1):2785-2794 (1990)	

EXAMINER SIGNATURE:	/Lynn Bristol/	DATE CONSIDERED:	08/16/2011
------------------------	----------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Please place an "X" in this column if English translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	6235-75996-01
	Application Number	10/582,654
	Filing Date	February 20, 2008
	First Named Inventor	Ono
	Art Unit	1643
	Examiner Name	Lynn Anne Bristol

Examiner Initials*	Cite No. (optional)	OTHER DOCUMENTS	T**
/L.B./		BROWN <i>et al.</i> , "Integrin-associated protein (CD47) and its ligands," <i>Trends Cell Biology</i> , 11(3):130-135 (2001)	
↑		BURGESS <i>et al.</i> , "Possible dissociation of the heparin-binding and mitogenic activities of heparinbinding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue," <i>J. Cell Biol.</i> , 111:2129-2138 (1990)	
		BURRONE <i>et al.</i> , "Stimulation of HLA-A,B,C by IFN- α . The derivation of Molt 4 variants and the differential expression of HLA-A,B,C subsets," <i>The EMBO Journal</i> , 4(11):2855-2860 (1985)	
		BURTHEM <i>et al.</i> , "Hairy cell interactions with extracellular matrix: expression of specific integrin receptors and their role in the cell's response to specific adhesive proteins," <i>Blood</i> , 84(3):873-882 (1994)	
		CALDAS <i>et al.</i> , "Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen," <i>Mol. Immunol.</i> , 39:941-952 (2003)	
		CANGEMI <i>et al.</i> , "IFN- α mediates the up-regulation of HLA class I on melanoma cells without switching proteasome to immunoproteasome," <i>International Immunology</i> , 15(12):1415-1421 (2005)	
		CAPLUS Accession Number 2005:547624, 2 pages (2008)	
		CARON <i>et al.</i> , "Engineered Humanized Dimeric Forms of IgG Are More Effective Antibodies," <i>J. Exp. Med.</i> , 176:1191-1195 (1992)	
		CHIEN <i>et al.</i> , "Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism," <i>Proc. Nat. Acad. Sci. USA</i> , 86:5532-5536 (1989)	
		CHIRGIN <i>et al.</i> , "Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease," <i>Biochemistry</i> , 18(24):5294-5299 (1979)	
		COOPER <i>et al.</i> , "Transendothelial migration of neutrophils involves integrin-associated protein (CD47)," <i>Proc. Natl. Acad. Sci. USA</i> , 92:3978-3982 (1995)	
		DE LEÓN <i>et al.</i> , "High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study," <i>BMC Cancer</i> , 9(48):1-9 (2009)	
		DE SAUVAGE <i>et al.</i> , "Stimulation of Megakaryocytopoiesis and Thrombopoiesis by the c-Mpl Ligand," <i>Nature</i> , 369:533-538 (1994)	
		DE ST. GROTH and SCHEIDECKER, "Production of Monoclonal Antibodies: Strategy and Tactics," <i>Journal of Immunological Methods</i> , 35:1-21 (1980)	
		DILLMAN, "Monoclonal antibodies for treating cancer," <i>Ann. Int. Med.</i> , 111(7):592-603 (1989)	
		DORAI <i>et al.</i> , "Mammalian cell expression of single-chain Fv (sFv) antibody proteins and their C-terminal fusions with interleukin-2 and other effector domains," <i>Biotechnology</i> , 12(9):890-897 (1994)	

EXAMINER SIGNATURE: /Lynn Bristol/	DATE CONSIDERED: 08/16/2011
---	---------------------------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Please place an "X" in this column if English translation is attached.

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6235-75996-01
Application Number	10/582,654
Filing Date	February 20, 2008
First Named Inventor	Ono
Art Unit	1643
Examiner Name	Lynn Anne Bristol

Examiner Initials*	Cite No. (optional)	OTHER DOCUMENTS	T**
/L.B./		FELGENHAUER <i>et al.</i> "Nucleotide Sequences of the cDNAs Encoding the V-Regions of H- and LChains of a Human Monoclonal Antibody Specific to HIV-1 - gp41," <i>Nucleic Acids Research</i> , 18(16):4927 (1990)	
↑		FUJIMOTO <i>et al.</i> , "50-kD integrin-associated protein does not detectably influence several functions of glycoprotein IIb-IIIa complex in human platelets," <i>Blood</i> , 86(6):2174-2182 (1995)	
		FUKUSHIMA <i>et al.</i> , "Enhanced hematopoiesis in vivo and in vitro by splenic stromal cells derived from the mouse with recombinant granulocyte colony-stimulating factor," <i>Blood</i> , 80(8):1914-1922 (1992)	
		FUKUSHIMA <i>et al.</i> , "Apoptosis of Bone Marrow Cells Via Integrin Associated Protein by the Novel Monoclonal Antibody," <i>Blood</i> , 94(10):479A (1999)	
		GALFRE and MILSTEIN, "Preparation of monoclonal antibodies: strategies and procedures," <i>Methods in Enzymology</i> , 73:3-46 (1981)	
		GALFRE <i>et al.</i> , "Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG," <i>Nature</i> , 277:131-133 (1979)	
		GIUSTI <i>et al.</i> , "Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region," <i>Proc. Natl. Acad. Sci. USA</i> , 84:2926-2930 (1987)	
		GREENSPAN and DI CERA, "Defining epitopes: It's not as easy as it seems," <i>Nature Biotechnology</i> , 17:936-937 (1999)	
		GRELL <i>et al.</i> , "TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis," <i>Lymphokine and Cytokine Research</i> , 12(3):143-148 (1993)	
		GÜSSOW and SEEMANN, "Humanization of Monoclonal Antibodies," <i>Methods in Enzymology</i> , 203:99-121 (1991)	
		HOLLMIGER el at., "Specific Killing of Lymphoma Cells by Cytotoxic T-Cells Mediated by a Bispecific Diabody," <i>Protein Engineering</i> , 9(3):299-305 (1996)	
		HOPP <i>et al.</i> , "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification," <i>Biotechnology</i> , 6:1204-1210 (1988)	
		HORAN <i>et al.</i> , "Dimerization of the extracellular domain of granulocyte-colony stimulating factor receptor by ligand binding: a monovalent ligand induces 2:2 complexes," <i>Biochemistry</i> , 35:4886-4896 (1996)	
		HUSTON <i>et al.</i> , "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in <i>Escherichia Coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 85:5879-5883 (1988)	
		ITOH <i>et al.</i> , "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," <i>Cell</i> , 66:233-243 (1991)	
		JIANG <i>et al.</i> , "A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2," <i>J. Biol. Chem.</i> , 280(6):4656-4662 (2005)	
		JONES and BENDIG, "Rapid PCR-Cloning of Full-Length Mouse Immunoglobulin Variable Regions," <i>Biotechnology</i> , 9:88-89 (1991)	

EXAMINER
SIGNATURE:

/Lynn Bristol/

DATE
CONSIDERED:

08/16/2011

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Please place an "X" in this column if English translation is attached.

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6235-75996-01
Application Number	10/582,654
Filing Date	February 20, 2008
First Named Inventor	Ono
Art Unit	1643
Examiner Name	Lynn Anne Bristol

Examiner Initials*	Cite No. (optional)	OTHER DOCUMENTS	T**
/L.B./		KEARNEY, <i>et al.</i> , "A New Mouse Myeloma Cell Line That Has Lost immunoglobulin Expression But Permits The Construction of Antibody-Secreting Hybrid Cells Lines," <i>The Journal of Immunology</i> , 123(4):1548-1550 (1979)	
↑		KEEN <i>et al.</i> , "The use of serum-free medium for the production of functionally active humanized monoclonal antibody from NSO mouse myeloma cells engineered using glutamine synthetase as a selectable marker," <i>Cytotechnology</i> , 18(3):207-217 (1996)	
		KÖHLER and MILSTEIN, "Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion," <i>Eur. J. Immunol.</i> , 6:511-519 (1976)	
		KORTT <i>et al.</i> , "Recombinant anti-sialidase single-chain variable fragment antibody: Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex," <i>Eur. J. Biochem.</i> , 221:151-157 (1994)	
		KORTT <i>et al.</i> , "Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing fiveand ten- residue linkers form dimmers and with zero-residue linker a trimer," <i>Protein Engineering</i> , 10(4):423-433 (1997)	
		KOZAK, "At Least Six Nucleotides Preceding the AUG Initiator Codon Enhance Translation in Mammalian Cells," <i>J. Mol. Biol.</i> , 196:947-950 (1987)	
		LARRICK, <i>et al.</i> , "Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes From Single Hybridoma Cells," <i>Biotechnology</i> , 7:934-938 (1989)	
		LAW <i>et al.</i> , "Observations On The Effect Of A Folic-Acid Antagonist On Transplantable Lymphoid Leukemias In Mice," <i>Journal of the National Cancer Institute</i> , 10:179-192 (1949)	
		LAZAR <i>et al.</i> , "Transforming growth factor a: mutation of aspartic acid 47 and leucine 48 results in different biological activities," <i>Molecular and Cellular Biology</i> , 8:1247-1252 (1988)	
		LEI <i>et al.</i> , "Characterization of the <i>Erwinia carotovora pelB</i> Gene and Its Product Pectate Lyase," <i>Journal of Bacteriology</i> , 169:4379-4383 (1987)	
		LINDBERG <i>et al.</i> , "Molecular Cloning of Integrin-Associated Protein: An Immunoglobulin Family Member with Multiple Membrane-Spanning Domains Implicated in $\alpha_5\beta_3$ -Dependent Ligand Binding," <i>The Journal of Cell Biology</i> , 123(2):485-496, The Rockefeller University Press (1993)	
		LINDBERG <i>et al.</i> , "Rh-Related Antigen CD47 is the Signal-Transducer Integrin-Associated Protein," <i>J. Biol. Chem.</i> , 269:1567-1570 (1994)	
		LÖFFLER, "A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes," <i>Blood</i> , 95(6):2098-2103 (2000)	
		MARGULIES <i>et al.</i> , "Somatic Cell Hybridization of Mouse Myeloma Cells," <i>Cell</i> , 8:405-415 (1976)	
		MARIUZZA <i>et al.</i> , "The Structural Basis of Antigen-Antibody Recognition," <i>Ann. Rev. Biophys. Biophys. Chem.</i> , 16:139-159 (1987)	
		MATEO et al., "Induction of Apoptosis in B-Cells From Chronic Lymphocytic Leukemia (CLLs) by CD47," <i>FASEB Journal</i> , 12(5):A1082 (1998)	

EXAMINER SIGNATURE:	/Lynn Bristol/	DATE CONSIDERED:	08/16/2011
------------------------	----------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Please place an "X" in this column if English translation is attached.

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6235-75996-01
Application Number	10/582,654
Filing Date	February 20, 2008
First Named Inventor	Ono
Art Unit	1643
Examiner Name	Lynn Anne Bristol

Examiner Initials*	Cite No. (optional)	OTHER DOCUMENTS	T**
/L.B./		MATEO <i>et al.</i> , "CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia," <i>Nat. Med.</i> , 5(11):1277-1284 (1999)	
↑		MAWBY <i>et al.</i> , "Isolation and characterization of CD47 glycoprotein: a multispansing membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumor marker OA3," <i>Biochem. J.</i> , 304:525-530 (1994)	
		MCINNES and SCHETT, "Cytokines in the pathogenesis of rheumatoid arthritis," <i>Nature Reviews/Immunology</i> , 7:429-442 (2007)	
		METHIA <i>et al.</i> , "Oligodeoxynucleotides Antisense to the Proto-Oncogene <i>c-mpl</i> Specifically Inhibit In Vitro Megakaryocytopoiesis," <i>Blood</i> , 82(5):1395-1401 (1993)	
		MILILI <i>et al.</i> , "The VDJ Repertoire Expressed in Human preB Cells Reflects the Selection of <i>Bona Fide</i> Heavy Chains," <i>Eur. J. Immunol.</i> , 26:63-69 (1996)	
		MILLIGAN, "G Protein-Coupled Receptor Dimerization: Function and Ligand Pharmacology," <i>Mol. Pharm.</i> , 66:1-7 (2004)	
		MIZUSHIMA and NAGATA, "pEF-BOS, a Powerful Mammalian Expression Vector," <i>Nucleic Acids Research</i> , 18(17):5322 (1990)	
		MULLIGAN <i>et al.</i> , "Synthesis of Rabbit β-Globin in Cultured Monkey Kidney Cells Following Infection with a SV40 β-Globin Recombinant Genome," <i>Nature</i> , 277:108-114 (1979)	
		NAKAYAMA <i>et al.</i> , "Thrombocytosis in preterm infants: a possible involvement of thrombopoietin receptor gene expression," <i>Journal of Molecular Medicine</i> , 83:316-320 (2005)	
		O'BRIEN <i>et al.</i> , "Monoclonal antibodies for the human insulin receptor stimulate intrinsic receptor-kinase activity," <i>Biochem. Soc. Trans.</i> , 14(6):1021-1023 (1986)	
		PAUL, <i>Fundamental Immunology</i> , Raven Press, NY, Chapter 8, p. 235-282 (1993)	
		PAUL, <i>Fundamental Immunology</i> , 3rd Edition, Raven Press, NY, Chapter 9, pp. 292-295 (1993)	
		PETTERSEN <i>et al.</i> , "CD47 Signals T Cell Death," <i>J. Immunol.</i> , 162:7031-7040 (1999)	
		PETTERSON, "CD47 and death signaling in the immune system," <i>Apoptosis</i> , 5:299-306 (2000)	
		REFF and HEARD, "A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications," <i>Critical Reviews in Oncology and Hematology</i> , 40:25-35 (2001)	
		REINHOLD <i>et al.</i> , "In vivo expression of alternatively spliced forms of integrin-associated protein (CD47)," <i>J. Cell Science</i> , 108:3419-3425 (1995)	
		REITER <i>et al.</i> , "Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv," <i>Protein Engineering</i> , 7(5):697-704 (1994)	
		REITER <i>et al.</i> , "Stabilization of the Fv Fragments in Recombinant Immunotoxins by Disulfide Bonds Engineered into Conserved Framework Regions," <i>Biochemistry</i> , 33:5451-5459 (1994)	

EXAMINER SIGNATURE:	/Lynn Bristol/	DATE CONSIDERED:
------------------------	----------------	---------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Please place an "X" in this column if English translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	6235-75996-01
		Application Number	10/582,654
		Filing Date	February 20, 2008
		First Named Inventor	Ono
		Art Unit	1643
		Examiner Name	Lynn Anne Bristol

Examiner Initials*	Cite No. (optional)	OTHER DOCUMENTS	T**
/L.B./		RIECHMANN <i>et al.</i> , "Reshaping Human Antibodies for Therapy," <i>Nature</i> , 332:323-327 (1988)	
↑		ROUE <i>et al.</i> "Mitochondrial dysfunction in CD47-mediated caspase-independent cell death: ROS production in the absence of cytochrome c and AIF release," <i>Biochimie</i> , 85:741-746 (2003)	
↑		ROZSNYAY <i>et al.</i> , "Phenylarsine oxide (PAO) blocks antigen receptor-induced calcium response and tyrosine phosphorylation of a distinct group of proteins," <i>Immunology Lett.</i> , 37(2-3):197-205 (1993)	
↑		SACKSTEIN, "The lymphocyte homing receptors: gatekeepers of the multistep paradigm," <i>Current Opinion in Hematology</i> , 12:444-450 (2005)	
↑		SATO <i>et al.</i> , "Reshaping a Human Antibody to Inhibit the Interleukin 6-Dependent Tumor Cell Growth," <i>Cancer Research</i> , 53:851-856 (1993)	
↑		SCHICKEL, <i>et al.</i> , "Gene for Integrin-Associated Protein (IAP, CD47): Physical Mapping, Genomic Structure, and Expression Studies in Skeletal Muscle," <i>Biochem. Cell. Biol.</i> , 80(2):169-176 (2002)	
↑		SCHMIDT <i>et al.</i> , "A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor," <i>Int. J. Cancer</i> , 65(4):538-546 (1996)	
↑		SCHWARTZ <i>et al.</i> , "A 50-kDa Integrin-associated Protein Is Required for Integrin-regulated Calcium Entry in endothelial Cells," <i>J. Biol. Chem.</i> , 268(27):19931-19934 (1993)	
↑		SCOTT, "The Problem with Potency," <i>Nature Biotechnology</i> , 23(9):1037-1039 (2005)	
↑		SEKIMOTO <i>et al.</i> , "Eradication of human myeloma cells by a recombinant HLA class I-specific single chain Fv diabody," <i>45th Annual Meeting of the American Society of Hematology</i> , San Diego, CA, USA (December 6-9, 2003)	
↑		SEKIMOTO <i>et al.</i> , "Eradication of Human Myeloma Cells by a Recombinant HLA Class I-Specific Single Chain Fv Diabody," <i>Blood</i> , 102:932a, XP009106629 (Abstract #3469) (November 2003) [Abstract of the American Society of Hematology 45th Annual Meeting, December 6-9, 2003, San Diego, California]	
↑		SHIGETA <i>et al.</i> , "Sperm-immobilizing monoclonal antibody to human seminal plasma antigens," <i>Clin. Exp. Immunol.</i> , 42:458-462 (1980)	
↑		SHULMAN <i>et al.</i> , "A better cell line for making hybridomas secreting specific antibodies," <i>Nature</i> , 276:269-270 (1978)	
↑		SOUYRI <i>et al.</i> , "A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors," <i>Cell</i> , 63:1137-1147 (1990)	
↑		SPAARGAREN <i>et al.</i> , "Antibody-induced Dimerization Activates the Epidermal Growth Factor Receptor Tyrosine Kinase," <i>J. Biol. Chem.</i> , 266(3):1733-1739 (1981)	
↑		STANCOVSKI <i>et al.</i> , "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth," <i>Proc. Natl. Acad. Sci. USA</i> , 88:8691-8695 (1991)	

EXAMINER SIGNATURE: /Lynn Bristol/	DATE CONSIDERED: 08/16/2011
---	---------------------------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Please place an "X" in this column if English translation is attached.

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6235-75996-01
Application Number	10/582,654
Filing Date	February 20, 2008
First Named Inventor	Ono
Art Unit	1643
Examiner Name	Lynn Anne Bristol

Examiner Initials*	Cite No. (optional)	OTHER DOCUMENTS	T**
/L.B./		STEIN <i>et al.</i> , "Characterization of humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab," <i>Blood</i> , 108(8):2736-2744 (2006)	
↑		TROWBRIDGE, "Interspecies Spleen-Myeloma Hybrid Producing Monoclonal Antibodies Against Mouse Lymphocyte Surface Glycoprotein, T200," <i>J. Exp. Med.</i> , 148:313-323 (1978)	
		VERMA <i>et al.</i> , "Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems," <i>Journal of Immunological Methods</i> , 216:165-181 (1998)	
		VERNON-WILSON <i>et al.</i> , "CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPo 1," <i>Eur. J. Immunol.</i> , 30:2130-2137 (2000)	
		WHITLOW <i>et al.</i> , "Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv," <i>Protein Eng.</i> , 7(8):1017-1026 (1994)	
		WINKLER <i>et al.</i> , "Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody," <i>J. Immunol.</i> , 165:4505-4514 (2000)	
		XIE <i>et al.</i> , "Direct Demonstration of MuSK Involvement in Acetylcholine Receptor Clustering Through Identification of Agonist ScFv," <i>Nature Biotechnology</i> , 15(8):768-771 (1997)	
		YANABU <i>et al.</i> , "Tyrosine phosphorylation and p72 ^{syk} activation by an anti-glycoprotein Ib monoclonal antibody," <i>Blood</i> , 89(5):1590-1598 (1997)	
		YARDEN and SCHLESSINGER, "Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation," <i>Biochemistry</i> , 26(5):1434-1442 (1987)	
		YELTON <i>et al.</i> , "Fusion of Mouse Myeloma and Spleen Cells," <i>Current Topics in Microbiology and Immunology</i> , 81:1-7 (1978)	
		U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/530,696, mailed October 19, 2006, 8 pages	
		FISH & RICHARDSON P.C., Response to Restriction Requirement dated October 19, 2006, in U.S. App. Ser. No. 10/530,696, filed November 16, 2006, 1 page	
		U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed December 21, 2006, 19 pages	
		FISH & RICHARDSON P.C., Amendment in Reply to Office Action dated December 21, 2006 in U.S. App. Ser. No. 10/530,696, filed April 23, 2007, 16 pages	
		U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 10/530,696, mailed August 8, 2007, 13 pages	
		U.S. EXAMINER ANNE GUSSOW, USPTO Interview Summary in U.S. App. Ser. No. 10/530,696, mailed November 26, 2007, 3 pages	
		FISH & RICHARDSON P.C., Amendment in Reply to Office Action dated August 8, 2007 in U.S. App. Ser. No. 10/530,696, filed December 6, 2007, 12 pages	
		U.S. EXAMINER ANNE GUSSOW, USPTO Advisory Action in U.S. App. Ser. No. 10/530,696, mailed December 14, 2007, 3 pages	

EXAMINER SIGNATURE:	/Lynn Bristol/	DATE CONSIDERED:	08/16/2011
------------------------	----------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Please place an "X" in this column if English translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	6235-75996-01
	Application Number	10/582,654
	Filing Date	February 20, 2008
	First Named Inventor	Ono
	Art Unit	1643
	Examiner Name	Lynn Anne Bristol

Examiner Initials*	Cite No. (optional)	OTHER DOCUMENTS	T**
/L.B./		U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed February 5, 2008, 9 pages	
↑		FISH & RICHARDSON, Amendment in Reply to Action dated February 5, 2008 in U.S. App. Ser. No. 10/530,696, filed August 5, 2008, 7 pages	
		U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed November 17, 2008, 18 pages	
		FISH & RICHARDSON, Amendment in Reply to Action dated November 17, 2008 in U.S. App. Ser. No. 10/530,696, filed February 17, 2009, 14 pages	
		U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 10/530,696, mailed June 8, 2009, 10 pages	
		FISH & RICHARDSON, Amendment in Reply to Action dated June 8, 2009 in U.S. App. Ser. No. 10/530,696, filed November 30, 2009, 10 pages	
		U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed April 23, 2010, 9 pages	
		FISH & RICHARDSON, Amendment in Reply to Action dated January 7, 2011 in U.S. App. Ser. No. 10/530,696, filed June 1, 2011, 5 pages	
		International Search Report for App. Ser. No. PCT/JP2003/013063, mailed November 18, 2003, 2 pages	
		International Preliminary Examination Report for App. Ser. No. PCT/JP2003/013063, dated February 6, 2004, 4 pages	
		European Search Report for App. Ser. No. EP 03 75 1456, dated April 4, 2006, 2 pages	
		U.S. EXAMINER PENSEE T. DO, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,176, mailed October 19, 2009, 6 pages	
		FISH & RICHARDSON P.C., Response to Restriction Requirement dated October 19, 2009 in U.S. App. Ser. No. 10/582,176, filed November 4, 2009, 1 page	
		U.S. EXAMINER PENSEE T. DO, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,176, mailed January 25, 2010, 7 pages	
		FISH & RICHARDSON P.C., Amendment in Reply to Action dated January 25, 2010 in U.S. App. Ser. No. 10/582,176, filed July 23, 2010, 11 pages	
		U.S. EXAMINER PENSEE T. DO, USPTO Final Office Action in U.S. App. Ser. No. 10/582,176, mailed October 29, 2010, 11 pages	
		International Search Report for App. Ser. No. PCT/JP2004/018499, mailed January 18, 2005, 2 pages	
		International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018499, dated January 26, 2006, 5 pages	

EXAMINER SIGNATURE:	/Lynn Bristol/	DATE CONSIDERED:	08/16/2011
------------------------	----------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Please place an "X" in this column if English translation is attached.

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6235-75996-01
Application Number	10/582,654
Filing Date	February 20, 2008
First Named Inventor	Ono
Art Unit	1643
Examiner Name	Lynn Anne Bristol

Examiner Initials*	Cite No. (optional)	OTHER DOCUMENTS	T**
/L.B./		FISH & RICHARDSON P.C., Amendment in Reply to Action dated December 9, 2010 in U.S. App. Ser. No. 10/582,304, filed May 27, 2011, 5 pages	
		U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,413, mailed January 4, 2008, 8 pages	
		FISH & RICHARDSON P.C., Response to Restriction Requirement dated January 4, 2008 in U.S. App. Ser. No. 10/582,413, filed February 4, 2008, 2 pages	
		U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,413, mailed March 31, 2008, 17 pages	
		FISH & RICHARDSON P.C., Amendment in Reply to Action dated March 31, 2008 in U.S. App. Ser. No. 10/582,413, filed June 30, 2008, 20 pages	
		U.S. EXAMINER ANNE GUSSOW, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed June 30, 2008, 2 pages	
		U.S. EXAMINER BRADLEY DUFFY, USPTO Notice of Informal or Non-Responsive Amendment in U.S. App. Ser. No. 10/582,413, mailed October 20, 2008, 3 pages	
		U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed November 12, 2008, 4 pages	
		FISH & RICHARDSON P.C., Amendment in Reply to Notice of Informal or Non-Responsive Amendment dated October 20, 2008 in U.S. App. Ser. No. 10/582,413, filed November 17, 2008, 10 pages	
		U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed November 25, 2008, 4 pages	
		U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed December 24, 2008, 4 pages	
		U.S. EXAMINER BRADLEY DUFFY, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,413, mailed March 11, 2009, 8 pages	
		FISH & RICHARDSON P.C., Response to Restriction Requirement dated March 11, 2009 in U.S. App. Ser. No. 10/582,413, filed April 8, 2009, 8 pages	
		U.S. EXAMINER BRADLEY DUFFY, USPTO Final Office Action in U.S. App. Ser. No. 10/582,413, mailed June 25, 2009, 28 pages	
		U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed October 27, 2009, 4 pages	
		U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed December 2, 2009, 4 pages	
		U.S. EXAMINER BRADLEY DUFFY, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,413, mailed April 16, 2010, 27 pages	
		International Search Report for App. Ser. No. PCT/JP2004/018493, mailed March 22, 2005, 2 pages	

EXAMINER SIGNATURE:	/Lynn Bristol/	DATE CONSIDERED:	08/16/2011
------------------------	----------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Please place an "X" in this column if English translation is attached.

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6235-75996-01
Application Number	10/582,654
Filing Date	February 20, 2008
First Named Inventor	Ono
Art Unit	1643
Examiner Name	Lynn Anne Bristol

Examiner Initials*	Cite No. (optional)	OTHER DOCUMENTS	T**
/L.B./		International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018493, dated December 20, 2005, 7 pages	
		European Search Report for App. Ser. No. EP 04 82 0305, dated October 16, 2008, 3 pages	
		U.S. EXAMINER SHULAMITH H. SHAVER, USPTO Restriction Requirement in U.S. App. Ser. No. 12/874,872, mailed December 15, 2010, 6 pages	
		U.S. EXAMINER SHULAMITH H. SHAVER, USPTO Restriction Requirement in U.S. App. Ser. No. 10/548,727, mailed April 12, 2007, 6 pages	
		FISH & RICHARDSON P.C., Reply to Restriction Requirement dated April 12, 2007 in U.S. App. Ser. No. 10/548,727, filed May 3, 2007, 1 page	
		U.S. EXAMINER SHULAMITH H. SHAVER, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/548,727, mailed August 3, 2007, 21 pages	
		FISH & RICHARDSON P.C., Amendment in Reply to Action dated August 3, 2007 in U.S. App. Ser. No. 10/548,727, filed January 15, 2008, 15 pages	
		U.S. EXAMINER SHULAMITH H. SHAVER, USPTO Final Office Action in U.S. App. Ser. No. 10/548,727, mailed April 29, 2008, 23 pages	
		U.S. EXAMINER SHULAMITH H. SHAVER, USPTO Advisory Action in U.S. App. Ser. No. 10/548,727, mailed September 24, 2008, 6 pages	
		U.S. EXAMINER SHULAMITH H. SHAVER, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/548,727, mailed January 28, 2009, 16 pages	
		FISH & RICHARDSON P.C., Amendment in Reply to Action dated January 28, 2009 in U.S. App. Ser. No. 10/548,727, filed June 26, 2009, 9 pages	
		U.S. EXAMINER SHULAMITH H. SHAVER, USPTO Notice of Allowance in U.S. App. Ser. No. 10/548,727, mailed November 25, 2009, 29 pages	
		International Search Report for App. Ser. No. PCT/JP2004/003334, mailed June 15, 2004, 3 pages	
		International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/003334, dated May 2, 2005, 6 pages	
		International Search Report for App. Ser. No. PCT/JP2004/005152, mailed July 20, 2004, 2 pages	
		International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/005152, dated February 14, 2005, 6 pages	
		European Search Report for App. Ser. No. EP 04 72 6750, dated February 4, 2008, 3 pages	
		U.S. EXAMINER BRADLEY DUFFY, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/547,747, mailed June 1, 2009, 41 pages	

EXAMINER SIGNATURE:	/Lynn Bristol/	DATE CONSIDERED:	08/16/2011
------------------------	----------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Please place an "X" in this column if English translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	6235-75996-01
	Application Number	10/582,654
	Filing Date	February 20, 2008
	First Named Inventor	Ono
	Art Unit	1643
	Examiner Name	Lynn Anne Bristol

Examiner Initials*	Cite No. (optional)	OTHER DOCUMENTS	T**
/L.B./		FISH & RICHARDSON P.C., Amendment in Reply to Action dated June 1, 2009 in U.S. App. Ser. No. 11/547,747, filed November 30, 2009, 12 pages	
		U.S. EXAMINER BRADLEY DUFFY, USPTO Final Office Action in U.S. App. Ser. No. 11/547,747, mailed February 19, 2010, 15 pages	
		FISH & RICHARDSON P.C., Amendment in Reply to Action dated February 19, 2010 in U.S. App. Ser. No. 11/547,747, filed June 18, 2010, 13 pages	
		FISH & RICHARDSON, Amendment in Reply to Office Action of January 24, 2011 in Corresponding U.S. App. Ser. No. 11/910,117, filed June 23, 2011, 20 pages.	
		U.S. EXAMINER MEERA NATARAJAN, USPTO Restriction Requirement in U.S. App. Ser. No. 11/916,351, mailed September 3, 2010, 8 pages	
		FISH & RICHARDSON P.C., Amendment and Response to Restriction Requirement dated September 3, 2010 in U.S. App. Ser. No. 11/916,351, filed December 2, 2010, 9 pages	
		U.S. EXAMINER ANNE L. HOLLERAN, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/916,351, mailed March 3, 2011, 11 pages	
		International Search Report for App. Ser. No. PCT/JP2006/311575, mailed September 26, 2006, 7 pages	
		International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/311575, dated December 11, 2007, 5 pages	
		European Search Report for App. Ser. No. EP 06 75 7198, dated June 11, 2010, 2 pages	
		European Search Report for App. Ser. No. EP 06 76 6512, dated November 30, 2009, 7 pages	
		U.S. EXAMINER YUNSOO KIM, USPTO Restriction Requirement in U.S. App. Ser. No. 11/916,979, mailed July 1, 2010, 7 pages	
		FISH & RICHARDSON P.C., Amendment and Response to Restriction Requirement dated July 1, 2010 in U.S. App. Ser. No. 11/916,979, filed November 30, 2010, 9 pages	
		U.S. EXAMINER HONG SANG, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/916,979, mailed January 21, 2011, 15 pages	
		FISH & RICHARDSON P.C., Amendment in Reply to Action dated January 21, 2011 in U.S. App. Ser. No. 11/916,979 filed July 14, 2011, 20 pages	
		International Search Report for App. Ser. No. PCT/JP2006/311600, mailed August 29, 2006, 10 pages	
		International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/31160, dated December 11, 2007, 8 pages	
		International Search Report for App. Ser. No. PCT/JP2006/311625, mailed August 22, 2006, 5 pages	

EXAMINER SIGNATURE:	/Lynn Bristol/	DATE CONSIDERED:	08/16/2011
------------------------	----------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.
 **Please place an "X" in this column if English translation is attached.

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6235-75996-01
Application Number	10/582,654
Filing Date	February 20, 2008
First Named Inventor	Ono
Art Unit	1643
Examiner Name	Lynn Anne Bristol

Examiner Initials*	Cite No. (optional)	OTHER DOCUMENTS	T**
/L.B./		International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/311625, dated December 11, 2007, 4 pages	
/L.B./		U.S. EXAMINER YUNSOO KIM, USPTO Restriction Requirement in U.S. App. Ser. No. 11/916,981, mailed March 31, 2010, 5 pages	
/L.B./		FISH & RICHARDSON P.C., Response to Restriction Requirement dated March 31, 2010 and Preliminary Amendment in U.S. App. Ser. No. 11/916,981, filed September 29, 2010, 6 pages	
/L.B./		U.S. EXAMINER YUNSOO KIM, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/916,981, mailed December 3, 2010, 20 pages	
/L.B./		FISH & RICHARDSON P.C., Amendment in Reply to Action dated December 3, 2010 in U.S. App. Ser. No. 11/916,981, filed June 2, 2011, 18 pages	

EXAMINER SIGNATURE:	/Lynn Bristol/	DATE CONSIDERED:	08/16/2011
------------------------	----------------	---------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Please place an "X" in this column if English translation is attached.